Zahavi, Tamar
Salmon-Divon, Mali
Salgado, Roberto http://orcid.org/0000-0002-1110-3801
Elkin, Michael
Hermano, Esther
Rubinstein, Ariel M.
Francis, Prudence A. http://orcid.org/0000-0002-7207-9286
Di Leo, Angelo
Viale, Giuseppe
de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Ameye, Lieveke
Sotiriou, Christos http://orcid.org/0000-0002-5745-9977
Salmon, Asher
Kravchenko-Balasha, Nataly http://orcid.org/0000-0001-6943-7479
Sonnenblick, Amir http://orcid.org/0000-0003-1954-4633
Funding for this research was provided by:
Israel Cancer Association USA (2017-0140)
Israel Cancer Research Fund (16-116-CRCDA)
Article History
Received: 15 September 2020
Accepted: 11 May 2021
First Online: 28 May 2021
Competing interests
: R.S. reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. A.S. reports consulting or Advisory Role: Eli Lilly, Pfizer, Novartis, Roche. Travel or Accommodations, Expenses: Neopharm, Celgene, Medison, Speakers bureau: Teva, Roche, Pfizer, Novartis, Grant support: Novartis, Roche. The remaining authors declare no competing interests.